Placeholder Banner

BIO Congratulates Dr. Robert Califf on Confirmation as FDA Commissioner

February 24, 2016

Washington, D.C. (February 24, 2016) – The following statement may be attributed to Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood:

“BIO extends our congratulations to Dr. Califf on his confirmation as Commissioner of the FDA, a job that carries tremendous responsibility in protecting public health and advancing biotechnology innovation. Dr. Califf’s confirmation comes at a time of tremendous advances being made in biotechnology and regulatory science, and I am confident that he will provide the stability, leadership and confidence the public seeks from an agency entrusted with such a critical mission.

“We applaud Chairman Alexander and Ranking Member Murray for their bi-partisan leadership and cooperation throughout Dr. Califf’s confirmation process. We look forward to working with Dr. Califf to ensure that the FDA’s regulatory capabilities and science continue to keep pace with the tremendous progress taking place in biotechnology innovation.”

Upcoming BIO Events 

BIO International Convention
June 6-9, 2016
San Francisco, Calif.

13th Annual BIO Asia International Conference
March 15-16, 2016
Tokyo, Japan

World Congress on Industrial Biotechnology
San Diego, CA
April 17-20, 2016

BIO-Europe Spring
April 4-6, 2016
Stockholm, Sweden


###

 

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…